Aquinox Pharmaceuticals, Inc. (AQXP) Reaches $11.89 After 6.00% Down Move; 19 Bullish Analysts Covering Barclays PLC (LON:BARC)

January 7, 2018 - By Richard Conner

Among 28 analysts covering Barclays PLC (LON:BARC), 19 have Buy rating, 3 Sell and 6 Hold. Therefore 68% are positive. Barclays PLC had 346 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 19 by UBS. The firm has “Buy” rating given on Wednesday, April 27 by Haitong Securities. JP Morgan maintained the stock with “Overweight” rating in Tuesday, January 12 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, October 7. The company was maintained on Tuesday, March 28 by Credit Suisse. The firm has “Sell” rating given on Wednesday, September 27 by Citigroup. The rating was maintained by Deutsche Bank on Tuesday, April 26 with “Hold”. Macquarie Research maintained it with “Outperform” rating and GBX 310 target in Monday, September 14 report. The company was maintained on Tuesday, September 22 by Investec. The firm earned “Neutral” rating on Monday, August 1 by BNP Paribas. See Barclays PLC (LON:BARC) latest ratings:

07/12/2017 Broker: Jefferies Rating: Hold Old Target: GBX 216.00 New Target: GBX 205.00 Maintain
06/12/2017 Broker: Citigroup Rating: Sell Maintain
29/11/2017 Broker: Citigroup Rating: Sell Maintain
29/11/2017 Broker: Berenberg Rating: Hold New Target: GBX 200.00 Maintain
28/11/2017 Broker: UBS Rating: Buy Maintain
29/11/2017 Broker: HSBC Rating: Buy Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
29/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 230.00 New Target: GBX 230.00 Maintain
28/11/2017 Broker: Shore Capital Rating: Buy Maintain
27/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 230.00 New Target: GBX 230.00 Maintain
20/11/2017 Broker: Bank of America Rating: Buy Old Target: GBX 180.00 New Target: GBX 220.00 Upgrade

The stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) is a huge mover today! The stock decreased 2.62% or $0.32 during the last trading session, reaching $11.89. About 68,931 shares traded. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has risen 122.35% since January 7, 2017 and is uptrending. It has outperformed by 105.65% the S&P500.The move comes after 8 months negative chart setup for the $279.00M company. It was reported on Jan, 7 by Barchart.com. We have $11.18 PT which if reached, will make NASDAQ:AQXP worth $16.74M less.

The stock decreased 2.60% or GBX 5.32 during the last trading session, reaching GBX 199.18. About 47.28M shares traded or 0.95% up from the average. Barclays PLC (LON:BARC) has 0.00% since January 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Barclays PLC, through its subsidiaries, provides various financial services and products worldwide. The company has market cap of 33.97 billion GBP. It offers personal and business banking services, credit cards, transactional and other lending products, and investment services and products. It currently has negative earnings. The firm also provides financial advice, primary capital raising and capital markets execution, risk and liquidity management, sales and trading, consumer payments, and wealth management services.

Analysts await Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to report earnings on March, 8. They expect $-0.65 EPS, down 35.42% or $0.17 from last year’s $-0.48 per share. After $-0.50 actual EPS reported by Aquinox Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 30.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>